Nabriva Therapeutics (FRA:NTY) Dividend Payout Ratio : 0.00 (As of Jun. 2023)

View and export this data going back to 2019. Start your Free Trial

What is Nabriva Therapeutics Dividend Payout Ratio?

Nabriva Therapeutics's dividend payout ratio for the months ended in Jun. 2023 was 0.00.

The historical rank and industry rank for Nabriva Therapeutics's Dividend Payout Ratio or its related term are showing as below:

FRA:NTY's Dividend Payout Ratio is not ranked ^*
in the Biotechnology industry.
Industry Median: 0.435
* Ranked among companies with meaningful Dividend Payout Ratio only.

As of today (2024-06-20), the Dividend Yield % of Nabriva Therapeutics is 0.00%.

Nabriva Therapeutics's Dividends per Share for the months ended in Jun. 2023 was €0.00.

The growth rate is calculated with least square regression.

For more information regarding to dividend, please check our Dividend Page.

Nabriva Therapeutics Dividend Payout Ratio Historical Data

The historical data trend for Nabriva Therapeutics's Dividend Payout Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Nabriva Therapeutics Dividend Payout Ratio Chart

Nabriva Therapeutics Annual Data

Trend

Dec13

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dividend Payout Ratio

Get a 7-Day Free Trial

Nabriva Therapeutics Quarterly Data
	Sep18	Dec18	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23
Dividend Payout Ratio	Get a 7-Day Free Trial															-	-	-	-	-

Competitive Comparison of Nabriva Therapeutics's Dividend Payout Ratio

For the Biotechnology subindustry, Nabriva Therapeutics's Dividend Payout Ratio, along with its competitors' market caps and Dividend Payout Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Nabriva Therapeutics's Dividend Payout Ratio Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Nabriva Therapeutics's Dividend Payout Ratio distribution charts can be found below:

* The bar in red indicates where Nabriva Therapeutics's Dividend Payout Ratio falls into.

Nabriva Therapeutics Dividend Payout Ratio Calculation

Dividend payout ratio measures the percentage of the company's earnings paid out as dividends.

Nabriva Therapeutics's Dividend Payout Ratio for the fiscal year that ended in Dec. 2022 is calculated as

Dividend Payout Ratio	=	Dividends per Share (A: Dec. 2022 )	/	EPS without NRI (A: Dec. 2022 )
	=	0	/	-20.126
	=	N/A

Nabriva Therapeutics's Dividend Payout Ratio for the quarter that ended in Jun. 2023 is calculated as

Dividend Payout Ratio	=	Dividends per Share (Q: Jun. 2023 )	/	EPS without NRI (Q: Jun. 2023 )
	=	0	/	0
	=	N/A

Nabriva Therapeutics (FRA:NTY) Dividend Payout Ratio Explanation

In dividends investing, Payout Ratio and Dividend Growth Rate are the two most important variables for consideration. A lower payout ratio may indicate that the company has more room to increase its dividends.

Nabriva Therapeutics Dividend Payout Ratio Related Terms

Thank you for viewing the detailed overview of Nabriva Therapeutics's Dividend Payout Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.

Nabriva Therapeutics (FRA:NTY) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Nabriva Therapeutics PLC (FRA:NTY) » Definitions » Dividend Payout Ratio

Comparable Companies

Traded in Other Exchanges

NBRVF:USA

Address

Alexandra House, Office 225/227, The Sweepstakes, Dublin, IRL, 4

Website

https://www.nabriva.com

Nabriva Therapeutics PLC is a clinical stage biopharmaceutical company. Nabriva is engaged in the research and development of novel anti-infective agents to treat serious infections, with a focus on the pleuromutilin class of antibiotics. The company has developed a product candidate, XENLETA, a semi-synthetic pleuromutilin antibiotic that is the first in its class for oral and IV administration in humans. XENLETA is designed to inhibit the synthesis of a specific protein on the bacterial ribosome. It operates in one reportable segment, which comprises the research and development of novel anti-infective agents to treat serious infections. The firm has commercial rights to two approved products, SIVEXTRO and XENLETA, as well as one development product candidate, CONTEPO.

Nabriva Therapeutics (FRA:NTY) Headlines

No Headlines